Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
7
Neutral
3
Bullish
4
Bearish
11
Neutral
3
Bullish
32
Bearish
4
Neutral
0
Bullish
28
Discovery themes featuring this stock
Gland Pharma Limited is a prominent player in the global generic injectables market, operating under a B2B model with essential services like contract development and manufacturing across various systems.
The company achieved broad-based revenue growth of 22% YoY in Q3 FY26, reaching INR 16,954 million, driven by both its expansion and integration of Cenexi in France.
Gland Pharma is actively expanding cartridge fill and finish capacities from 40 million to 140 million units, signifying growth potential in its complex product pipeline.
The acquisition of Cenexi increased Gland Pharma's footprint in Europe and enhanced its manufacturing capabilities, leading to a diversified revenue stream.
Strategic initiatives, including partnerships and CDMO contracts, position Gland Pharma for sustained growth, focusing on high-value, differentiated products.
Pharmaceuticals & Biotechnology
Pharmaceuticals
29,362 Cr
Low Risk
33.8
32.2
1.1
3.1
2,130.00
1,382.10
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1439.00 | 37,478 Cr | 40.13 | 5.05 | 0.27 | 13.33 | 17.89 | 7.73 | ||
2895.85 | 34,931 Cr | 35.68 | 8.10 | 1.00 | 22.56 | 27.85 | 17.89 | ||
1993.00 | 31,998 Cr | 43.15 | 8.41 | 0.75 | 18.88 | 25.16 | 16.00 | ||
1680.70 | 30,187 Cr | 36.63 | 6.37 | 0.19 | 16.72 | 19.37 | 9.53 | ||
1740.05 | 29,362 Cr | 33.84 | 3.07 | 1.01 | 8.27 | 12.46 | 7.18 | ||
1348.20 | 22,869 Cr | 1021.14 | 5.01 | 0.00 | 1.54 | 4.05 | -0.12 | ||
4859.30 | 22,037 Cr | 26.04 | 5.73 | 3.43 | 18.36 | 24.12 | 18.53 | ||
| Median: 7 Co. | — | 1740.05 | 30,187 Cr | 36.63 | 5.73 | 0.75 | 16.72 | 19.37 | 9.53 |
Upcoming Result Date: May 14, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Gland Pharma Ltd (GLAND) is currently trading at 1,795.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gland Pharma Limited is a prominent player in the global generic injectables market, operating under a B2B model with essential services like contract development and manufacturing across various systems. The company achieved broad-based revenue growth of 22% YoY in Q3 FY26, reaching INR 16,954 million, driven by both its expansion and integration of Cenexi in France. Gland Pharma is actively expanding cartridge fill and finish capacities from 40 million to 140 million units, signifying growth potential in its complex product pipeline. The acquisition of Cenexi increased Gland Pharma's footprint in Europe and enhanced its manufacturing capabilities, leading to a diversified revenue stream. Strategic initiatives, including partnerships and CDMO contracts, position Gland Pharma for sustained growth, focusing on high-value, differentiated products.
Over the past 52 weeks, Gland Pharma Ltd has traded between a low of ₹1,382.10 and a high of ₹2,130.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gland Pharma Ltd has a market capitalization of approximately 29,362.07. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gland Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.84 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 29,362.07 Cr, Gland Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gland Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gland Pharma Ltd is 33.84. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The text reports a latest price of ₹1,751.1, up ₹26.79, with the day’s range between ₹1,741.20 and ₹1,782.80.
The most significant announcement is the 'Biopharma Shakti' scheme, which allocates ₹10,000 crore over five years to make India a global hub for manufacturing biologics and biosimilars, directly aligning with Gland Pharma's strategic focus.
The share price jumped over 9% due to strong Q3 FY26 financial results, which included a 37% year-on-year increase in net profit and a 22% rise in revenue.
Gland Pharma reported a 27.7% year-on-year increase in consolidated net profit to ₹261 crore. Revenue from operations grew by 22.5% to ₹1,695 crore for the quarter ended December 31, 2025.
Earnings Call
Gland Pharma will host an earnings conference call on May 15, 2026 at 18:30 IST (60 mins) to discuss financial performance and business updates for the quarter and year ended March 31, 2026; transcript/audio to be posted on its website.
Board Meeting - Results
Gland Pharma will hold a Board meeting on May 15, 2026 to consider and approve audited standalone and consolidated financial results for Q4/FY ended Mar 31, 2026 and to consider recommending a final dividend; investor call at 18:30 IST; trading window reopens May 18.
Results & Dividend
Gland Pharma will hold a board meeting on 15-May-2026 to consider and approve audited standalone and consolidated results for Q4 and FY ended 31-Mar-2026 and to consider/recommend a final dividend; investor call at 18:30 IST.
